Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 12/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.39 |
| ▸ | CASP3 | P42574 | 5/20 | 0.38 |
| ▸ | CASP7 | P55210 | 5/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325192 | 0.89 | TLR9 (0.38) | TLR9TLR8TLR7GSK3B | |
| SCHEMBL2324337 | 0.87 | TLR9 (0.36) | TLR9TLR8TLR7GSK3B | |
| SCHEMBL2324317 | 0.87 | TLR9 (0.31) | TLR9TLR8TLR7 | |
| SCHEMBL15482407 | 0.87 | HTT (0.32) | — | |
| SCHEMBL2323235 | 0.85 | TLR9 (0.32) | TLR9TLR8TLR7 | |
| SCHEMBL2326997 | 0.84 | SRC (0.37) | TLR9TLR8TLR7 | |
| SCHEMBL2325503 | 0.84 | SRC (0.37) | TLR9TLR8TLR7 | |
| SCHEMBL2324968 | 0.83 | SRC (0.38) | TLR9TLR8TLR7 | |
| SCHEMBL2326487 | 0.83 | SRC (0.38) | TLR9TLR8TLR7 | |
| SCHEMBL2321689 | 0.81 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534151-B1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2018-11-14 | — | — | EP | claimed |
| US-8658794-B2 | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof | MERCK SHARP & DOHME B.V. (NL) | 2014-02-25 | — | — | US | claimed |
| EP-2534151-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MSD Oss B.V. (NL) | 2012-12-19 | — | — | EP | claimed |
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2012-12-06 | — | — | US | claimed |
| WO-2011095556-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2011-08-11 | — | — | WO | claimed |
| EP-2534151-B1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2018-11-14 | — | — | EP | disclosed |
| US-8658794-B2 | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof | MERCK SHARP & DOHME B.V. (NL) | 2014-02-25 | — | — | US | disclosed |
| EP-2534151-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MSD Oss B.V. (NL) | 2012-12-19 | — | — | EP | disclosed |
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2012-12-06 | — | — | US | disclosed |
| WO-2011095556-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | LCK, ZAP70, FYN | CDK9 317/4885CCNT1 2379/4885TLR9 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.